T here is undoubtedly renewed worldwide interest in transplantation of solid organs from asystolic (non-heart beating) donors. This includes several successful schemes in the UK, including recently performing one of the first asystolic lung transplants. It is possible that in the future more solid organs will be retrieved from these patients than from heart beating (brain stem dead) organ donors. Dr. Bell (JICS 4 (3): 76-7) summarises areas of acknowledged concern about non-heart beating organ donor (NHBOD) schemes, in particular the definition of futility and the potential for conflict of interest when deciding to withdraw active treatment. All the issues he raises are important and need to be debated by the intensive care community for the successful development of NHBOD schemes in the UK. The first myth to dispel is the concept of the NHBOD as a marginal donor.
Marginal donors?
NHBOD is not new. All organs for transplantation were obtained from asystolic donors until 1968 when the World Medical Association confirmed that brain stem death equated to somatic death. Subsequently many centres abandoned NHBOD as it became apparent that the outcome of organs from brain stem dead heart beating donors was superior to that from asystolic donors. However centres in the UK and elsewhere continued NHBOD schemes, developing superior methods of organ preservation and assessment of function before transplantation As a result the outcomes of kidneys transplanted from NHBOD rivals those achieved from brain stem dead heart beating donors. Early results of liver and lung transplantation from NHBODs are also encouraging. The results achieved in one UK transplant centre in the first year after the introduction of a NHBOD confirms that although there is a higher delayed graft function from asystolic donors, the long-term outcome is similar (Figure 1) . Similarly a large recent study (1) comparing the long term outcome of 122 transplanted kidneys from asystolic donors compared to 122 matched kidneys from brain stem dead heart beating donors over a 15 year period reported virtually identical outcomes in the two groups, 79 % of kidneys from asystolic donors functioning well at 10 years ( 1). As it becomes increasingly clear that these organs can no longer be considered as marginal, it is likely that more NHBOD schemes will be introduced in the UK. However it is important to remember that NHBOD has always been with us.
Withdrawal of treatment
The withdrawal of treatment is common in intensive care practice in Europe, the UK and the USA, being involved in 50 to 90 % of all deaths in the ICU (2-6). The decision to withdraw treatment is based not only on the recognition of futility of treatment, but also the potential suffering of patients as a result of continued treatment, the degree of disability should they survive and the patient's own wishes, if known. The concept of futility and treatment withdrawal is well recognised and supported by numerous bodies such as the Catholic Church (7, 8) , the BMA (9), the GMC (10) and numerous legal cases. It is impossible to have an absolute definition for futility since this is defined by what individual patients (rather than relatives or carers) decide is futile. Its recognition is one of the most important roles of an ITU consultant. In the setting of NHBOD we do not believe there is any conflict of interest, so long as the decision to withdraw treatment is made in the usual manner by the intensive care team, the family and the referring team, and that the transplant team plays no part in this decision making process. Similarly there is no conflict of interest when an intensivist performs the criteria to confirm death of the brain stem, since this is done primarily to stop futile intervention and not to enable organ transplantation.
Dr. Bell notes correctly that an application to the courts is required before nutrition or hydration can be withdrawn from patients in a persistent vegetative state (PVS). However it is inappropriate and misleading to compare this to treatment withdrawal decisions in ITU. The distinction revolves around ordinary and extraordinary treatment. Ordinary treatment is simple and effective, offering benefit without undue expense, pain, or suffering (e.g. oxygen, antibiotics, hydration & nutrition) and some consider such treatment obligatory. Extraordinary treatment may involve pain, expense and suffering and offer marginal benefit (e.g. ventilation, tracheostomies, inotropes, dialysis) and may be withdrawn when futility has been recognised as to do otherwise would permit suffering without the expectation of a meaningful recovery12. Furthermore the "treatment" that is being withdrawn in pvs is nutrition, considered by some to be a basic human right rather than medical treatment. This is why legal ratification was sought in the Tony Bland case (11) .
In the ICU setting treatment may be withdrawn when futility has been recognised (12) , to avoid subjecting patients with an extremely poor prognosis to uncomfortable, distressing and demeaning treatment when there is no reasonable expectation of any meaningful recovery. If treatment is not in the best interests of the patient then withdrawing treatment should not be any different ethically than withholding it (13) . In the absence of an advance directive then information from the relatives regarding the wishes of the patient become extremely important in the decision making process. The intensivist acts the patient advocate and must do what is in their best interests, including withdrawing treatment when appropriate. The timing of treatment withdrawal is influenced by many factors but the wishes of the family must remain paramount. It is for the transplant team to organise themselves around the time agreed with the patients' family.
Clearly it is a fundamental and deeply held principle in transplantation that the process of donation should not harm the donor. We are in complete agreement with Dr Bell that the administration of drugs (inotropes, heparin) or any escalation of treatment to enable organ donation is inappropriate and unacceptable practice once the decision to withdraw treatment has been reached. Equally we believe that femoral catheterisation under local anaesthesia before the declaration of death is unlikely to be acceptable practice in the UK. Our experience to date suggests that none of these practices is necessary in successful NHBOD programmes and are not being proposed in the UK. This is different to the practice of elective ventilation (14), which as Dr Bell points out is illegal. In elective ventilation not only was treatment (intubation and mechanical ventilation) being initiated that was not in the patient's best interests, but also that intervention could potentially harm some dying patients by 'enabling' them to survive, but with significant handicap.
The role of Intensive Care in donation
We believe that intensivists should support and facilitate new initiatives to enable organ donation and transplantation, but that these initiatives should be led by intensivists and be developed according to good ethical principles in accordance with the law, professional bodies and patients. We are morally obliged to facilitate organ donation for a patient if that was their expressed desire whilst alive, and also because it helps grieving families and is beneficial for society as a whole. We agree that certain issues regarding NHBOD need clarification to support the Table 1 . Long Term Outcome of kidney grafts from NHBOD (from reference 1). NHBOD = non-heart beating organ donor HBD = heart beating organ donor (BSD = brain stem dead)
NHBOD n=122 HBD (BSD) n=122
Primary non function 5.7% 4.9%
Delayed graft function 48% 23%
Graft survival 1 year 92% 91%
Graft survival 5 years 84% 82%
Graft survival 10 years 79% 77%
practice in the future. To this end the ICS is currently developing guidelines for NHBOD to be incorporated into an update of the 1999 guidelines for organ donation and management of the potential organ donor (14). We hope that they will help clarify some of these issues and form the basis of a national framework since as Dr Bell points out, it is not up to individual practitioners to decide on such issues as the duration of 'hands off' time following the certification of death certification or whether carrying a donor card or being on the transplant register constitutes an advance directive. The acceptance of NHBOD schemes by the general public is also an important consideration. Experience at the ICU at Frenchay suggests that relatives are more likely to agree to organ donation after treatment withdrawal and the onset of aystole. In the first 18 months of the NHBOD scheme relatives refused the offer of non-heart beating organ donation in 15% of patients, compared to a national refusal rate of approximately 50% for organ donation from brain stem dead patients.
The introduction of more NHBOD schemes could impact greatly on patients awaiting transplants in the UK and reduce the number of patients awaiting transplantation for the first time in a decade. Currently the waiting list for transplantation continues to grow while the number of donors and transplant procedures has remained static ( Figure  2) . The potential donor audit has demonstrated that following a diagnosis of brain stem death, around 90% of relatives are asked about organ donation and around 50% of these allow it to proceed. Estimating around 2000 brain stem death tested patients in the UK annually, it is clear that increasing donation from brain stem dead donors alone is unlikely to make a significant impact patients waiting for organ transplantation.
Conclusion
We agree with Dr Bell that there are challenges associated with NHBOD and that it is for intensivists rather than the transplant services to take up the challenge and to formulate a an acceptable code of conduct involving regulation and audit. The code of practice currently being developed, under the auspices of the ICS should hopefully reassure both clinicians and the public. We should also accept that the development and drive for organ donation from ICU patients is our responsibility and not that of the transplant community. We need to take on these challenges and establish an ethical framework of practice that protects our patients whilst also enabling donation to proceed where appropriate. In doing so, we could contribute to a successful transplant programme by reducing the number of patients awaiting transplantation and dramatically improving the quality of life of patients with end organ failure. ! Conflict of interest: SB is the lead clinician for the donor liaison scheme and both authors are consultant leads for the donor liaison scheme within their hospitals.
